AstraZeneca PLC
EU lobbying footprint — who they meet, and on what. Built only from official disclosures, every meeting cited.
AstraZeneca PLC has 90 disclosed EU lobbying meetings from 2021-01-11 to 2026-10-20: 36 with the European Commission and 54 with Members of the European Parliament. Source: EU Transparency Register no. 249402638316-62, Commission disclosures and MEP declarations.
Lobbying profile
as declared 2026-03-24- Category
- Companies & groups
- Legal status
- Public Limited Company
- Declared lobbying cost
- €800,000
- Lobbying FTEs
- 4.35
- Members
- 5
Files it’s lobbying on
The org's disclosed policy areas, ranked by number of meetings.
Declared fields of interest
Business and industry · Climate action · Consumers · Digital economy and society · Economy, finance and the euro · Education and training · Employment and social affairs · Environment · Foreign affairs and security policy · International co-operation and development · Public health · Research and innovation
At a glance
The officials and MEPs most often met, by disclosed-meeting count.
- Olivér Várhelyi4
- Sandra Gallina4
- Laszlo Kristoffy3
- Saila Rinne2
- Rainer Becker2
Disclosed meetings
Newest first, showing the most recent 60 of 90. EC = European Commission, EP = Member of the European Parliament.
- 2026-10-20ECSaila Rinne · Head of UnitExchange on the role of digital health and AI in transforming healthcare, particularly in oncologysource ↗
- 2026-10-14ECOlivér Várhelyi · Cabinet of Commissioner Olivér VárhelyiEU-Mexico health cooperationsource ↗
- Biotech Actsource ↗
- 2026-09-30ECOlivér Várhelyi · Cabinet of Commissioner Olivér VárhelyiPharma manufacturing in Europesource ↗
- 2026-09-08ECRainer Becker · DirectorExchange on the Biotech Act and other legislative filessource ↗
- 2026-09-08ECFlavio Facioni · Cabinet of Commissioner Olivér VárhelyiHealth packagesource ↗
- Health policysource ↗
- 2026-07-09ECCarmen Laplaza Santos · Head of UnitHealthcare Systems Transformationsource ↗
- 2026-07-06ECVilija Sysaite · Cabinet of Executive Vice-President Stéphane SéjournéEU Pharmaceuticals Competitiveness Industrial chemical / sustainability policy Biotech Actsource ↗
- 2026-07-03ECOlivér Várhelyi · Cabinet of Commissioner Olivér VárhelyiLife Sciences Roundtablesource ↗
- availability of medicinessource ↗
- Biotech Actsource ↗
- EU Biotech Actsource ↗
- 2026-06-02ECAnn-Sofie Ronnlund · Cabinet of Commissioner Ekaterina ZaharievaLife sciencessource ↗
- 2026-05-06ECLaszlo Kristoffy · Cabinet of Commissioner Olivér VárhelyiHealth packagesource ↗
- Biotech Actsource ↗
- 2026-04-28ECJana Dabbelt · Cabinet of Commissioner Olivér VárhelyiEUCOPE - Strasbourgsource ↗
- Biotech actsource ↗
- 2026-03-31ECPaulina Dejmek Hack · Cabinet of Commissioner Jessika RoswallSustainable technologiessource ↗
- Biotech Actsource ↗
- EU Biotech Act Isource ↗
- 2026-03-12ECJessika Roswall · Cabinet of Commissioner Jessika RoswallDiscussion on innovation in Europe. And exchange of views on the topic PFAS.source ↗
- 2026-03-05ECPatricia Reilly · Cabinet of President Ursula von der LeyenExchange on EU health and industrial policiessource ↗
- Health Policysource ↗
- Biotechsource ↗
- Health Policysource ↗
- Biotech Act 1source ↗
- 2026-02-03ECCarmen Laplaza Santos · Head of UnitExchange of views on the competitiveness of the European pharmaceutical sector.source ↗
- 2026-01-21ECLaszlo Kristoffy · Cabinet of Commissioner Olivér VárhelyiHealth Packagesource ↗
- 2026-01-21ECOlivér Várhelyi · Cabinet of Commissioner Olivér VárhelyiHealth Packagesource ↗
- 2025-12-03ECUlla Schwager · Head of UnitExchange of views on developments in the pharmaceutical industry and aspects of competition law and policy enforcement in this industry sectorsource ↗
- Pharmaceutical legislationsource ↗
- 2025-11-18ECSaila Rinne · Head of UnitAI in health.source ↗
- 2025-10-07ECChiara Galiffa · Cabinet of Commissioner Maroš ŠefčovičUS and EU trade relations in the context of the pharmaceutical sectorsource ↗
- Current health situation in the EUsource ↗
- Clinical trials policysource ↗
- 2025-09-04ECRainer Becker · DirectorExchange of views on multinational clinical trials in the context of the upcoming Biotech Actsource ↗
- Health policysource ↗
- CMAsource ↗
- 2025-07-14ECPatricia Reilly · Cabinet of President Ursula von der LeyenCompetitiveness of the biopharmaceutical sectorsource ↗
- Critical Medicines Actsource ↗
- Critical medicinessource ↗
- Meeting CMAsource ↗
- SANTsource ↗
- Competitividad del sectorsource ↗
- Patient rightssource ↗
- Health policysource ↗
- PFASsource ↗
- Introductory meetingsource ↗
- 2025-04-23ECVilija Sysaite · Cabinet of Executive Vice-President Stéphane SéjournéTrade, simplification, IPsource ↗
- 2025-03-28ECLaszlo Kristoffy · Cabinet of Commissioner Olivér VárhelyiDiscussion about EU priorities in the area of public health.source ↗
- 2025-03-24ECAnn-Sofie Ronnlund · Cabinet of Commissioner Ekaterina ZaharievaLife Sciences Strategysource ↗
- 2025-03-24ECVita Jukne · Cabinet of Commissioner Jessika RoswallThe climate-health nexus, Urban Wastewater Treatment Directive and PFAS restrictionsource ↗
- 2025-03-24ECIvan Dimov · Cabinet of Commissioner Ekaterina ZaharievaLife Sciences Strategysource ↗
- Medicinessource ↗
- Pharmaceutical strategysource ↗
- Medcicinessource ↗
- Health policysource ↗
- Ongoing negotations on GPLsource ↗
- Competitiveness of the pharmaceutical sector in Europesource ↗
Frequently asked
How many EU lobbying meetings has AstraZeneca PLC disclosed?
AstraZeneca PLC (EU Transparency Register no. 249402638316-62) appears in 90 disclosed meetings with EU officials and MEPs between 2021-01-11 and 2026-10-20: 36 with the European Commission and 54 with Members of the European Parliament.
What does AstraZeneca PLC lobby on?
AstraZeneca PLC's disclosed EU meetings most often concern Health, Technology, Trade, Climate. Every meeting and its topic is listed with its official source on this page.
Who does AstraZeneca PLC meet in Brussels?
Across its disclosed meetings, AstraZeneca PLC has met Commission officials including Olivér Várhelyi, Sandra Gallina, Laszlo Kristoffy, and MEPs including SOKOL Tomislav, CICCIOLI Carlo, POLFJÄRD Jessica. These are counts of officially disclosed meetings, not a measure of influence.
Primary sources
Every meeting above is a public disclosure by the European Commission or a Member of the European Parliament; counts are of disclosed meetings only and are not a measure of influence. Methodology. Data © European Union (Decision 2011/833/EU) & the European Parliament.
Related on the graph
The same footprint, mapped onto the topics and files it touches.
Get the EU lobbying brief
We’ll email you when major new lobbying meetings are disclosed — free, no account, built from public EU data with every entry cited. We only email on real updates.
See your company’s overlap with AstraZeneca PLC — and the rest of the corpus.
Enter your company and Lex builds a cited Exposure Map in about 30 seconds. Free, no login.